Protecting with Purpose.
You treat complex disease that others won’t and high-risk patients rely on you to improve their quality of life.
Complex case volume is increasing in the cath lab due to the presence of complex coronary artery disease, hemodynamic compromise, and co-morbidities. PCI case volume with major complications or comorbidities (MCCs), or 4+ vessels or stents has grown from 23% to 30% in the last four years.1 Protected PCI with Impella may improve quality of life, lower the rates of acute kidney injury2, and has been shown to be cost effective for the healthcare system.
The use of Impella in patients with severe coronary artery disease is supported by FDA PMA approval, clinical society guidelines, and the 2015 ACC/HFSA/SCAI/STS consensus publication support the use of Impella devices in patients with reduced or normal left ventricular function and severe coronary artery disease for treatment of anticipated technically challenging or prolonged PCI patients5.
Learn more and access resources on how a Protected PCI with Impella can help you successfully treat the most challenging patients.
University Hospitals PCI Algorithm
Protected PCI Dossier - 2018
Protected PCI Pocket Brochure
SUBSCRIBE TO THE DIGITAL COMMUNITY
Receive weekly updates including case reviews, tips and tricks, specialists opinions, and resources and downloads regarding Protected PCI and Cardiogenic Shock.
- Coordinating Care of Complex Coronary Artery Disease Patients. September 2017. Optum Advisory Board.
- Flaherty MP, et al. Circ Res. 2017
- Abiomed data on file, PROTECT II
- O'neill W. et al. Circulation. 2012 Oct 2:126(14):1717-27
- Rihal, C. Naidu, S, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. J Am Coll Cardiol. 2015 May 19;65(19):e7-e26. doi: 10.1016/j.jacc.2015.03.036. Epub 2015 Apr 7.